Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy. Patients given sitagliptin in addition ...
Sep 29, 2020
0
285
(HealthDay)—For healthy adults and individuals with well-controlled type 2 diabetes (T2D), a single dose of the dipeptidyl peptidase-4 inhibitor sitagliptin is associated with increased standardized insulin secretion, with ...
Dec 20, 2017
0
2
(HealthDay)—For patients with type 2 diabetes, the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin stimulates distal tubular natriuresis, according to a study published online May 26 in Diabetes Care.
Jun 9, 2017
0
0
Sitagliptin (trade names: Januvia and Xelevia) is approved for certain adults with type 2 diabetes mellitus whose blood-glucose levels are inadequately controlled by diet and exercise alone. The fixed combination with metformin ...
Oct 13, 2016
0
0
(HealthDay)—For patients with new-onset diabetic ketoacidosis (DKA) and severe hyperglycemia, metformin and sitagliptin treatment after normoglycemia remission correlate with increased relapse-free survival and prolonged ...
Sep 2, 2016
0
0
The German Institute for Quality and Efficiency in Health Care (IQWiG) analysed additional data on drugs from the group of gliptins. The drug manufacturers had subsequently submitted these data to the Federal Joint Committee ...
Oct 9, 2013
0
0
Some blood-sugar-lowering drugs have caused kidney problems in patients with type 2 diabetes, so physicians are especially cautious when prescribing these agents to diabetics who also have chronic kidney disease (CKD).
Nov 13, 2011
0
0
Two newer drugs used to treat Type 2 diabetes could be linked to a significantly increased risk of developing pancreatitis and pancreatic cancer, and one could also be linked to an increased risk of thyroid cancer, according ...
Sep 16, 2011
0
0
